Schizophrenic Disorders Clinical Trial
Official title:
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
The study is a randomized clinical trial investigating the efficacy of a comprehensive psychological intervention for the treatment of first episode schizophrenia
Patients suffering from their first episode of schizophrenic disorders are randomly
allocated to either a short "information centered psychoeducation" (ICP) of 8 sessions or a
"cognitive behavioral treatment" (CBT). CBT includes 8 sessions of psychoeducation, 8
sessions of computer based cognitive training, 8 sessions with relatives and 20 sessions of
focusing on stress management, relapse prevention and coping with persistent symptoms.
The primary endpoint is relapse at the one and two year follow up.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04608032 -
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
|
N/A | |
| Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
| Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
| Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
| Completed |
NCT01606436 -
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
|
Phase 1 | |
| Completed |
NCT02525315 -
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
|
Phase 2 | |
| Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
| Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
| Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
| Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
| Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
| Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
| Terminated |
NCT05164289 -
Interest of EMDR Schizophrenic Disorders
|
||
| Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
| Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
| Completed |
NCT02544516 -
Upside Down, Give me the Handle
|
N/A | |
| Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |